Podcasts about clinical trials

Send us a textProphylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm.Baud O, Lehert P; PREMILOC study group.Eur J Pediatr. 2025 Jun 14;184(7):419. doi: 10.1007/s00431-025-06248-9.PMID: 40515786 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textFrom Warm to Cold: Feeding Cold Milk to Preterm Infants with Uncoordinated Oral Feeding Patterns.Ferrara-Gonzalez L, Kamity R, Htun Z, Dumpa V, Islam S, Hanna N.Nutrients. 2025 Apr 26;17(9):1457. doi: 10.3390/nu17091457.PMID: 40362766 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textNorepinephrine versus Dopamine for Septic Shock in Neonates: A Randomized Controlled Trial.Mazhari MYA, Priyadarshi M, Singh P, Chaurasia S, Basu S.J Pediatr. 2025 Jul;282:114599. doi: 10.1016/j.jpeds.2025.114599. Epub 2025 Apr 17.PMID: 40252959 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Attention: The first clinical trial testing creatine for Alzheimer's just dropped, and the results are absolutely mind-blowing. In this episode, I've sat down with Max Lugavere at The White House to discuss the new research on creatine. This pilot study gave 20 Alzheimer's patients 20 grams of creatine daily for 8 weeks. The results? Statistically significant improvements across nearly every cognitive measurement.  Join the Ultimate Human VIP community and gain exclusive access to Gary Brecka's proven wellness protocols today!: https://bit.ly/4ai0Xwg Get Max Lugavere book, “Genius Foods”: https://theultimatehuman.com/book-recs Want to dive deeper into brain health? Watch Max's documentary "Little Empty Boxes" here: https://bit.ly/47Qf8Y9 Listen to Max Lugavere's "The Genius Life" podcast weekly on all your favorite platforms: https://bit.ly/47MyoWK Connect with Max Lugavere: Website: https://bit.ly/3XLOGdN YouTube: https://bit.ly/4eJc6r7 Instagram: https://bit.ly/3BsEf7y Facebook: https://bit.ly/3Y4QkZr TikTok: https://bit.ly/3Y8ov2w X.com: https://bit.ly/3ZMQgPk LinkedIn: https://bit.ly/4eGVrEw Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GENETIC TEST: ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 01:30 Getting Back to the Basics 02:17 Clinical Trial on Creatine  05:57 Impact of Creatine on Health 11:26 Spreading Awareness on Positive Healthcare Choices The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

Send us a textDr. Mitchell Rothstein joins Dr. Michael Koren to wake us up to the dangers of insomnia. Insomnia is a common sleep disorder affecting approximately 30% of adults and is characterized by poor sleep on at least three nights a week for three months or more. Dr. Rothstein reviews what insomnia is, what is happening in the brain, and what sufferers can do about it. He explains how lifestyle changes can make a big difference, especially in our digital world. Dr. Rothstein then reviews the effectiveness of cognitive behavior therapy, common over-the-counter treatments, prescription medicines, and when it's time to see a sleep specialist.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Supplements and Resources:

The FDA's Diversity Action Plan guidance underwent several changes in recent months—with the draft guidance taken down, restored, and then pulled again—creating uncertainty for sponsors planning Phase III and pivotal trials across all therapeutic areas. With the final guidance expected by June 26, CRO regulatory leaders reflected on how companies can manage this evolving environment. They explored: The impact of the FDA's changing Diversity Action Plan guidance on sponsors' trial planning How companies adapted strategies to maintain inclusivity goals amid shifting regulatory priorities Broader implications for trial design, pipeline strategies, and sponsor approaches in the global drug development landscape This episode is part 2 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we'll continue exploring the key forces shaping the future of clinical trials. Listen to part 1 here: https://insights.citeline.com/scrip/partnered-content/podcast-series-navigating-regulatory-changes-market-dynamics-cro-perspectives-on-the-future-of-clinical-trials-26Q4Q35N6BHTZGLHIKHK6V2NXY/

A Northwestern Medicine clinical trial led by Rod Passman, MD, could improve the way we care for millions of people with atrial fibrillation, but it is facing an unexpected challenge. There has been a pause in federal funding to Northwestern University that could impact this study's progress. While the trial has not been ordered to stop, all National Institutes of Health funding to Northwestern University has been frozen, raising questions about how long this potential life-saving work can go on without a resolution.  

When in one's neuroendocrine cancer journey might a clinical trial be considered? What factors influence treatment decisions, including whether to pursue a clinical trial? Dr. Alexandria Phan, medical oncologist at the Medical College of Wisconsin, offers thoughtful guidance on when and how clinical trials fit into the neuroendocrine cancer journey. This episode helps demystify the clinical trial process and empowers patients to engage in meaningful, proactive conversations with their care teams.MEET DR. ALEXANDRIA PHANDr. Alexandria Phan is a hematologist and medical oncologist at the Froedtert & Medical College of Wisconsin. Clinical practice, clinical research and education are three pillars important to Dr. Phan's approach to cancer care. Her areas of focus for clinical research and patient care are neuroendocrine tumors and malignancies of the gastrointestinal system. She has held several leadership positions, including cancer center director, founding program director for Hematology-Oncology fellowship, medical director of clinical research, and national director for GI cancer program.For more information, visit NCF.net.

Send us a textDr. Michael Koren joins Kevin Geddings to explain biomarkers, which he describes as biological indicators that may mark the presence of disease. Researchers are increasingly looking at biomarkers for their potential in early detection of disease before symptoms appear. Dr. Koren brings it home with a personal story of how current research studies looking into lung cancer biomarkers may have real-world effects for participants.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

LINK TO ACRO'S RBQM SUMMARY REPORT: https://www.acrohealth.org/rbqm-summary-report/In this episode, ACRO RBQM Working Group members Lauren Garson (Veeva), Cris McDavid (Parexel), and Jennifer Stewart (Premier Research) joined ACRO's Good Clinical Podcast to discuss key takeaways from ACRO's annual RBM/RBQM Landscape Survey. Since 2019, ACRO's RBQM survey has dug into trial-level data on industry adoption of RBM and RBQM components. Informed by conversations with FDA, the aim of the survey is to evaluate ACRO member companies' adoption of risk-based monitoring to better understand how the larger framework of risk-based quality management (RBQM) are being adopted across the clinical trial industry.  

Sona Nanotech CEO David Regan joined Steve Darling from Proactive at a key BioTech conference in Boston to announce a significant milestone for the company in the development of its innovative cancer treatment technology. Sona has officially entered into a clinical trial agreement with Bradford Hill in Chile to conduct an early feasibility study of its Targeted Hyperthermia Therapy, focusing on patients with advanced melanoma. The study will enroll up to ten patients who have previously been treated with, but failed to respond to, standard immunotherapy protocols. The trial is designed to assess the safety, tolerability, and preliminary efficacy of Sona's THT approach. Each participant will receive two treatments spaced one week apart, applying Sona's novel photothermal therapy to hard-to-treat tumors. Pending final ethics committee approval, patient enrollment is expected to begin by the end of June, with interim results anticipated later this summer and final results projected for fall 2025. Regan emphasized that this feasibility study will play a crucial role in advancing the clinical development of THT, providing the first in-human data to support its future application across broader patient populations and cancer types. Sona's Targeted Hyperthermia Therapy is a cutting-edge photothermal cancer treatment that uses gold nanorods to deliver heat directly to solid tumors. These nanorods are introduced into the tumor site, where they absorb infrared light, converting it into localized therapeutic heat that can help destroy cancerous tissue without harming surrounding healthy cells. Regan noted that the company is optimistic about the study's outcomes and sees this trial as a potential catalyst for broader clinical adoption, strategic partnerships, and future regulatory submissions. With early results expected in just a few months, Sona Nanotech is well-positioned to advance its mission of transforming cancer treatment through targeted nanotechnology-driven therapies. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTherapy #GoldNanorods #FDAApproval #BiotechNews #Immunotherapy #ClinicalTrials #Nanomedicine #DrugSafety #CancerTherapy #TargetedHyperthermia #ClinicalTrials #MelanomaTreatment #BiotechNews #MedicalDevices #Immunotherapy #HealthcareInnovation #ProactiveInvestors

Send us a textAI promises to revolutionize clinical trials and reshape regulatory oversight. But is the pharma industry ready? And can the FDA keep pace with the technology? In this episode of the HealthBiz Podcast, host David Williams is joined by Tom Doyle, Chief Technology Officer of Medidata, to discuss the promises and potential pitfalls of AI in clinical trials.

Send us a textSteve Satek joins Dr. Michael Koren to share his journey from bench researcher to founding his own community clinical trial site. The entrepreneur describes how he pioneered embedding clinical research directly in Chicago neighborhoods to form a strong integration with the community. He talks about the importance of building trust through education and by helping the community where you are. They talk about how a strong relationship with your community members is vital to the success of research and patient outcomes.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.   Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc." "There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."  #BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO bioaccessla.com Download the transcript here

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.   Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc." "There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."   #BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO bioaccessla.com Listen to the podcast here  

Julio Martinez-Clark, co-founder and CEO of contract research organization (CRO) bioaccess®️, joins hosts Michael Roberts and Scott Zeitzer to discuss why Latin America is a great place for clinical trials for medical devices. Julio explains how both the startup and the patients benefit from studies conducted in Latin America, and what startups should be thinking about as they get ready to begin first-in-human studies. Hosted on Acast. See acast.com/privacy for more information.

That's one of the questions being posed today at a conference organised by the Institute of Clinical Trials. To tell us more Professor Fidelma Dunne, Director of the Institute for Clinical Trials at the University of Galway.

Dr. David Furman and Dr. Buck Joffrey discuss the complexities of immune aging, the role of inflammation in age-related diseases, and how artificial intelligence is being utilized to enhance research in this field. He introduces the concept of the inflammatory age clock, which measures biological aging through immune system signals, and explores potential therapeutic interventions, including nutraceuticals and therapeutic plasma exchange. The discussion also touches on the future of aging research, emphasizing personalized approaches and the democratization of diagnostics. Learn more about Dr. David Furman: https://www.buckinstitute.org/lab/furman-lab/

Send us a textDr. Koren reflects on conversations with Harvard Medical School classmates who shared stories about struggling to navigate the healthcare system despite their medical training. Clinical trials provide valuable structure and support to help patients navigate healthcare complexities, offering personalized attention often unavailable in traditional medical settings.• Harvard Medical School graduates find healthcare navigation difficult, highlighting challenges for average patients• Case study of 78-year-old with heart failure who was accidentally overdosed on medications after discharge• Clinical trials break down complex health information into clear protocols • Research coordinators help patients understand treatments and communicate with other providers• Studies available for congestive heart failure patients, including both types of heart failure• Harvard classmates will be featured on upcoming MedEvidence episodesVisit EncoreDocs.com to learn more about participating in clinical trials, or call 904-730-0166. For reliable medical information, check out MedEvidence.com - the truth behind the data, a better alternative to "Dr. Google."Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In 2024, ACRO announced its D&I Site Resource Grants Program. Designed to support an innovative 12-month pilot project, the site resource grants act as a platform to incubate innovative strategies for improving representative enrollment in clinical research.  On this episode, site grantee representatives Dr. Ammara Mushtaq, MD (Brooklyn Clinical Research), Dr. Lovie Negrin, APRN (Randomize Now), and Sandra Carmona Torres, BSN (K2 Medical Research) join the podcast to discuss the lessons learned through implementing their pilot projects so far. They dive deeper into how sites can address barriers to participation, the need for consistent investment in building trust and engaging local community members, and the state of clinical research from a site perspective.

Send us a textDr. Michael Koren interviews Lavern Dowell, an advanced registered nurse practitioner who specializes in diabetes care. They discuss her approach to treating the whole person and how mental health can impact everything from diet and exercise to the ability to go see a physician. They also emphasize the need to increase diversity in medical research and the importance of delivering diagnoses with sensitivity to avoid causing shame to patients.Learn more about Lavern's practice here: https://www.dowellmedical.org/Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Episode 053 | Dr. Marthe Dika, MD, FAAD is a board-certified dermatologist and proud owner of M. Dika Dermatology, with practices located in Burlington and Glendale, Wisconsin. At her clinics, she welcomes patients of all ages and skin types, offering comprehensive care for diseases of the skin, hair, and nails. Dr. Dika is particularly experienced in and passionate about managing hair loss and has helped many people who struggle with this often devastating problem.In addition to her clinical work, Dr. Dika is involved in advancing the field ofdermatology through clinical trials conducted at her two locations. Her dedication to research allows her to remain at the forefront of dermatologic advancements and offer her patients cutting edge treatment options.She earned her medical degree from the Medical College of Wisconsin in Milwaukee and completed her residency in dermatology at the University of Iowa. Dr. Dika's commitment to patient care coupled with her passion for dermatology ensures that all who visit M. Dika Dermatology receive the highest quality care tailored to their individual needs.Shout out to Dr. Dika's mentor, Dr. Chesahna Kindred, as mentioned in this episode! Thanks to all the great mentors out there for all that you do. And shout out to the absolutely delightful Whitney Hubbell, PharmD, IBCLC. Dr. Hubbell is currently an all-star Medical Science Liaison at Sanofi, and I'm grateful to her for introducing me to Dr. Dika.This episode was recorded on February 3rd, 2025.Connect with and learn from Dr. DikaM. Dika DermatologyInstagramFacebookMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

Vaccines have become one of the most polarizing topics in public health, and frankly, for valid reasons. What we've witnessed over the past few years is an unprecedented breakdown in trust between medical institutions and the public - and that didn't happen in a vacuum.What is the truth about Vaccine Safety and Efficacy? Dr. Roger McFillin sits down with vaccine safety epidemiologist Allison Krug to expose the hidden forces shaping public health, from vaccine safety to the weaponization of fear. They dive deep into the failures of placebo-controlled trials, the truth about natural immunity vs. vaccine-induced immunity, and why good evidence is harder to find than you think. Allison shares what she learned working inside the pharmaceutical industry and reveals how mindset, belief systems, and disconnection from nature and spirituality are fueling today's chronic illness crisis. If you've ever questioned mainstream medicine or want to reclaim your health and autonomy, this conversation will change how you see the world.00:00 Introduction00:05:32 The Danger of Outsourcing Health to "Experts"00:20:45 Mindset, Pain, and the Illusion of Powerlessness00:42:49 Consciousness and the Healing Power Within01:05:32 Germ Theory, Genetics, and the Loss of Agency01:15:47 Awakening to Frequencies: A Spiritual Revolution01:22:23 Dark Spiritual Forces and the Battle for Consciousness01:31:27 How Public Schools Crush Creativity and Independence01:49:05 Medical Paradigm Flaws: What They're Not Telling You01:55:40 Spiritual Emptiness: The Hidden Cost of Modern Culture02:00:12 Radical Responsibility and the Return to Divine LoveAllision Krug WebsiteAllision Krug on XAllison Krug on Megyn Kelly COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities  Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode of “Moving Medicine Forward,” host Jeremy Strand sits down with Brian Lawrence, Chief Financial Officer at CTI, to explore how strategic financial planning is critical to advancing clinical trials, particularly in rare disease research. Brian shares insights on balancing profitability with purpose in one of the world's most highly regulated industries, reflecting on early career decisions, global expansion, trial funding challenges, and the growing influence of AI in finance. 00:36 Brian shares how early interests in math and accounting, along with a few great mentors, led him into finance and the clinical research space. 02:17 Why Brian opted for a smaller accounting firm over a Big Four company and how that decision shaped his career. 03:16 How his love for process improvement and early experiences with digital transformation prepared him for the dynamic contract research organization (CRO) environment. 04:03 Brian discusses CTI's evolution: growing four times in size, expanding globally, and staying true to its rare disease focus. 05:00 The challenge of maintaining profitability while upholding the highest standards in research and compliance. 06:00 Brian explains the hidden costs of operating globally, including banking, compliance, and cybersecurity.  07:10 Why financial planning is critical in biotech, where projects can be halted suddenly due to safety or funding concerns. 09:00How investment trends and economic shifts post-COVID have tightened budgets and forced CROs and sponsors to adapt. 10:00 Brian breaks down the financial implications of trial diversity, especially in rare diseases with complex study designs. 11:12 The role of AI and digital tools in modern CRO operations, and why CTI is taking a deliberate approach to adoption. 13:00 Brian sees technology as a way to eliminate low-value tasks and empower finance teams to focus on strategic insights. 14:00 Through initiatives like CTI Cares and “Mission Moments,” Brian explains how CTI connects internal teams to the bigger picture of patient impact. 

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC). --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The discussion covers real-world UTUC cases, highlighting diagnostic challenges, treatment options, and evidence-based management strategies. They address scenarios ranging from localized to advanced UTUC, the role of systemic therapies, perioperative treatments, and the potential for novel approaches with immune checkpoint inhibitors. The episode underscores the evolving landscape of UTUC treatment and the importance of clinical trials and emerging biomarkers in improving patient outcomes. --- TIMESTAMPS 00:00 - Introduction 02:49 - Case Study 1: 66-Year-Old Male with UTUC11:19 - Case Study 2: 73-Year-Old Male with High-Grade Urothelial Carcinoma28:11 - Intravesical Chemotherapy Protocols30:44 - Case Study 3: 57-Year-Old Male with Recurrent Urothelial Cancer41:25 Clinical Trials and Emerging Treatments45:40 Case Study: 55-Year-Old Female with Bulky Lymphadenopathy 56:45 Concluding Remarks and Future Directions --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

In this episode, Jonathan Norman (Director, Localisation Services, YPrime) and Laura Russell (Senior Vice President, Head of Data and AI Product Development, Advarra) join the podcast to discuss how artificial intelligence is transforming today's clinical operations. They dive deeper into how AI can be used to improve protocol design, drive efficiency in localization processes, and modernize clinical operations to expand access to trials and get treatments to patients sooner. 

Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capitalIn this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovationTimestamps:[00:00:47] Why LATAM Is the Next MedTech Trial Hub[00:02:21] The Problem with FIH Trials in the U.S.[00:04:42] How bioaccess® Reduces Approval Timelines by 70%[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?[00:10:43] The Fundraising Pressure Behind Faster Clinical Results[00:12:22] Founder Mistakes in In-House Trial Management[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume[00:17:26] Regulatory Standards, UNESCO, and Regional Quality[00:20:10] Julio Outside the Office: Family, Fitness & PodcastingGet in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/Learn more about Bioaccess - https://www.bioaccessla.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the motivations of clinical trial veterans who repeatedly participate in medical research studies. Dr. Koren shares that these participants consistently cite the desire to "Make a Difference" as their primary motivation, pushing science and medicine forward for generations to come.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Carol Harvey's powerful journey from experienced nurse to breast cancer survivor offers a unique dual perspective that changes everything.Carol shares her unexpected triple-negative breast cancer diagnosis in September 2020 during the height of COVID restrictions when family couldn't accompany her to treatments. With 35 years of nursing experience and a role teaching future nurses at Liberty University, Carol brought professional knowledge to her patient experience that provided both advantages and surprising challenges.Her decision to join a clinical trial stands as perhaps the most fascinating aspect of this conversation. Despite her medical background, Carol experienced the vulnerability all patients feel when considering experimental treatments. The outcome? Extraordinary monitoring that included multiple echocardiograms, rapid tumor response, and a comprehensive team approach that left her feeling exceptionally well-cared for. "If I were to go through the whole thing again, I would jump into a clinical trial again, 100%," she reflects.Through chemotherapy, surgery, radiation, and even cognitive therapy for "chemo brain," Carol's journey spans numerous departments within Centra Health. Now three years post-treatment with regular follow-ups, she finds herself transformed. "I am such a better person on this side of cancer than I was beforehand," she reveals, describing a deeper faith, greater empathy, and profound perspective shift that turns even "bad hair days" into moments of gratitude. Her powerful closing message resonates for anyone facing difficult circumstances: "I can do hard things." Listen now to experience this remarkable story of professional insight meeting personal transformation.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they've made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.   Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP Clinical Research Coordinator Touro-Cancer Center New Orleans, LA   “We know that diversity is a big point, not only as per new FDA guidance, but [to] ensure that every participant is given an equal opportunity to hear about the study. [Our] approach is not to target a certain group of individuals. Really the approach is to target any individual that looks potentially eligible.” - Oluwakemi “Kemi” Oladipupo   Resources:  Community Oncology Can Close the Gap in Cancer Research Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator The Role of the Clinical Trials Navigator — [MINI PODCAST] EP 129 Human-Centered Design: A Possible Solution to Rural Clinical Trial Enrollment

Register free at https://brightu.com to watch the full Healing Revolution stream - Breaking News and Upcoming Segments (0:00) - Microscopy of Bio Sludge (2:04) - Bio Sludge as a Vector for Bioterrorism (4:03) - Details of the Chinese Couple's Case (7:23) - Potential for Bioterrorism and EPA's Role (11:51) - Microscopy of Bio Sludge: Dry Condition (17:54) - Microscopy of Bio Sludge: Incubated Condition (39:25) - Moderna Vaccine Approval and RFK Jr. (53:26) - Elon Musk's Criticism of Trump's Bill (1:07:07) - Ukraine War and Financial Corruption (1:12:41) - AI and Humanity's Future (1:17:40) - Self-Awareness in Life Forms (1:20:40) - Artificial Intelligence and Self-Awareness (1:27:51) - The Potential Dangers of AI (1:32:30) - AI's Impact on Infrastructure and Society (1:37:07) - The Role of Light in Healing (1:46:09) - The Healing Revolution Docu Series (1:47:06) - The Importance of Combining Therapies (1:50:03) - The Role of Light in Activating Nutrients (1:51:34) - The Impact of Light on Cancer Treatment (2:33:08) - The Role of Light in Detoxification (2:35:26) - LED vs. Incandescent/Halogen Bulbs (2:36:33) - Wavelengths and Their Therapeutic Benefits (2:38:13) - Dual LED Technology and Natural Intelligence (2:39:45) - Practical Applications and Humanitarian Efforts (2:42:09) - Healing Revolution Course and Additional Resources (2:45:53) - Long COVID Study and Remission Rates (2:47:42) - Final Thoughts and Call to Action (2:50:30) - Health Ranger's Preparedness Tips (2:51:47) - Iodine Supplements and Their Benefits (2:56:14) - Conclusion and Final Remarks (2:58:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Xiong returns to the platform in a special episode brought to you by Medable to explore the evolving role of AI in modernizing clinical trials. Their conversation covers how life sciences teams are leveraging AI to streamline data workflows, accelerate study readiness, and maintain regulatory compliance in both decentralized and traditional models. Throughout the episode, Xiong shares insights into the growing importance of integrating structured and unstructured data across trial systems — from clinical notes to imaging and lab results. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Europe Notified Body survey report - 31 October 2024 - What is the main Surprise: https://health.ec.europa.eu/document/download/59b9d90e-be42-4895-9f6f-bec35138bb0a_en?filename=md_nb_survey_certifications_applications_en.pdf The MIR form has been updated - Version 7.3.1 - Don't use previous versions: https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance/pmsv-reporting-forms_en   UK: UK MIR and FSCA - Change is in the AIR: https://www.gov.uk/government/publications/more-implementation/gb-mir-and-fsca-schema-implementation-guide UK MDR 2002 is dying - Long life to UK MDR 2025: https://www.legislation.gov.uk/ukdsi/2025/9780348269529 : Real-World Data or Clinical Trial or Both?- This is the question: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions     Training EU MDR Green Belt June 2025 - June 23rd, June 27th: https://school.easymedicaldevice.com/course/gb34/ eTraining on Vigilance and Audit preparation - Self-paced: https://school.easymedicaldevice.com/emd-course   ROW USA Q-Sub update  - New electronic template: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-q-submissions   Brazil: SIUD or UDI in Brazil - Manual of Use in Portuguese: https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/temas-em-destaque/arquivos/manual_siud_v01.pdf   Saudi Arabia: Series of Webinar - June is a Busy month in Saudi Arabia: 16 June 2025 Companion Diagnostic Regulatory Requirements: https://www.sfda.gov.sa/en/workshop/3540492 17 June 2025 Saudi Unique Device Identification (SAUDI-DI): https://www.sfda.gov.sa/en/workshop/3540493 19 June 2025 Artificial Intelligence and Machine Learning: https://www.sfda.gov.sa/en/workshop/3540495 23 June 2025 Digital Health Medical Devices regulatory approach: https://www.sfda.gov.sa/en/workshop/3540496 24 June 2025 Medical Devices Risk Classification: https://www.sfda.gov.sa/en/workshop/3540497 Saudi In-house Devices - Not like EU: https://www.sfda.gov.sa/sites/default/files/2025-05/MDS-G022En.pdf   Turkey: In Turkey, Economic Operators are Liable - Even after discontinuation or temporary stop of supply: https://titck.gov.tr/duyuru/tibbi-cihazlarin-tedarikinin-kesintiye-ugramasi-veya-durdurulmasi-sona-ermesi-durumunda-i-ktisadi-i-sletmecilerin-yukumlulukleri-hakkinda-duyuru-21052025113350   PODCAST: Podcast Nostalgia - What happened in May 2025 Episode 334 - What is the new UK Post-Market Surveillance Requirements? With Claire Dyson: https://podcast.easymedicaldevice.com/334-2/ Episode 335 - When is Regulatory Affairs needed during Design? With Aouda Ouzza: https://podcast.easymedicaldevice.com/335-2/ Episode 336 - is EHDS dangerous for Medical Device Manufacturers? With Cecile van der Heijden: https://podcast.easymedicaldevice.com/336-2/ Episode 337 - How Deepeye Medical overcame the AI Act? With Carmen Bellebna; https://podcast.easymedicaldevice.com/337-2/ Episode 338 - Trapped or Strategic? Changing Notified Bodies During MDR transition: https://podcast.easymedicaldevice.com/338-2/  

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.